
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Combining Immune Checkpoint Inhibitors and Anti-Angiogenesis Approaches: Treatment of Advanced Non-Small Cell Lung Cancer - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="152543E98AF2EFB30543E900673EC0E6.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="medsci">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371936/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Medical Sciences">
<meta name="citation_title" content="Combining Immune Checkpoint Inhibitors and Anti-Angiogenesis Approaches: Treatment of Advanced Non-Small Cell Lung Cancer">
<meta name="citation_author" content="Tate Barney">
<meta name="citation_author_institution" content="Boonshoft School of Medicine, Dayton, OH 45435, USA; barney.32@wright.edu">
<meta name="citation_author" content="Anita Thyagarajan">
<meta name="citation_author_institution" content="Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Dayton, OH 45435, USA; anita.thyagarajan@wright.edu">
<meta name="citation_author" content="Ravi P Sahu">
<meta name="citation_author_institution" content="Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Dayton, OH 45435, USA; anita.thyagarajan@wright.edu">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="13">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="143">
<meta name="citation_doi" content="10.3390/medsci13030143">
<meta name="citation_pmid" content="40843765">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371936/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371936/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371936/pdf/medsci-13-00143.pdf">
<meta name="description" content="Combining immune checkpoint inhibitors (ICIs) and anti-angiogenic pharmacologic agents is an encouraging therapeutic approach in the treatment of non-small cell lung cancer (NSCLC). Currently, the only FDA-approved therapy combining an immune ...">
<meta name="og:title" content="Combining Immune Checkpoint Inhibitors and Anti-Angiogenesis Approaches: Treatment of Advanced Non-Small Cell Lung Cancer">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Combining immune checkpoint inhibitors (ICIs) and anti-angiogenic pharmacologic agents is an encouraging therapeutic approach in the treatment of non-small cell lung cancer (NSCLC). Currently, the only FDA-approved therapy combining an immune ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371936/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12371936">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.3390/medsci13030143"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/medsci-13-00143.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12371936%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12371936/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12371936/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371936/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-medsci.png" alt="Medical Sciences logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Medical Sciences" title="Link to Medical Sciences" shape="default" href="http://www.mdpi.com/journal/medsci" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Med Sci (Basel)</button></div>. 2025 Aug 19;13(3):143. doi: <a href="https://doi.org/10.3390/medsci13030143" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3390/medsci13030143</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Med%20Sci%20(Basel)%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Med%20Sci%20(Basel)%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Med%20Sci%20(Basel)%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Med%20Sci%20(Basel)%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Combining Immune Checkpoint Inhibitors and Anti-Angiogenesis Approaches: Treatment of Advanced Non-Small Cell Lung Cancer</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Barney%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Tate Barney</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Tate Barney</span></h3>
<div class="p">
<sup>1</sup>Boonshoft School of Medicine, Dayton, OH 45435, USA; barney.32@wright.edu</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Barney%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tate Barney</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Thyagarajan%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Anita Thyagarajan</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Anita Thyagarajan</span></h3>
<div class="p">
<sup>2</sup>Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Dayton, OH 45435, USA; anita.thyagarajan@wright.edu</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Thyagarajan%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Anita Thyagarajan</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sahu%20RP%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Ravi P Sahu</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Ravi P Sahu</span></h3>
<div class="p">
<sup>2</sup>Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Dayton, OH 45435, USA; anita.thyagarajan@wright.edu</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sahu%20RP%22%5BAuthor%5D" class="usa-link"><span class="name western">Ravi P Sahu</span></a>
</div>
</div>
<sup>2,</sup><sup>*</sup>
</div>
<div class="cg p">Editor: <span class="name western">Antoni Torres</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-medsci-13-00143">
<sup>1</sup>Boonshoft School of Medicine, Dayton, OH 45435, USA; barney.32@wright.edu</div>
<div id="af2-medsci-13-00143">
<sup>2</sup>Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Dayton, OH 45435, USA; anita.thyagarajan@wright.edu</div>
<div class="author-notes p"><div class="fn" id="c1-medsci-13-00143">
<sup>*</sup><p class="display-inline">Correspondence: <span>ravi.sahu@wright.edu</span></p>
</div></div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Antoni Torres</span></strong>: <span class="role">Academic Editor</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jun 23; Revised 2025 Aug 1; Accepted 2025 Aug 12; Collection date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 by the authors.</div>
<p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12371936  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40843765/" class="usa-link">40843765</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Combining immune checkpoint inhibitors (ICIs) and anti-angiogenic pharmacologic agents is an encouraging therapeutic approach in the treatment of non-small cell lung cancer (NSCLC). Currently, the only FDA-approved therapy combining an immune checkpoint inhibitor and a vascular endothelial growth factor (VEGF) inhibitor is atezolizumab, bevacizumab, and chemotherapy in first-line metastatic NSCLC patients. However, the combination of nivolumab, a programmed death-1 (PD-1) inhibitor, and bevacizumab has also shown encouraging results in patients with NSCLC with minimal adverse effects, respectively. This communication aims to highlight the efficacy of nivolumab and bevacizumab in NSCLC patients without sensitizing mutations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS proto-oncogene 1 (ROS1). In addition, the combination of nivolumab/atezolizumab and bevacizumab with other therapeutic agents is also discussed. We also underscore the adverse effects and limitations of such combinations in NSCLC patients. Future studies should focus on large-scale trials and biomarker identification to establish the benefits of these combination therapies in NSCLC patients.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> non-small cell lung cancer, anti-angiogenesis, immunotherapy, bevacizumab, nivolumab</p></section></section><section id="sec1-medsci-13-00143"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Lung cancer is one of the leading causes of cancer-related mortality worldwide and is the major cause of cancer deaths in the United States [<a href="#B1-medsci-13-00143" class="usa-link" aria-describedby="B1-medsci-13-00143">1</a>,<a href="#B2-medsci-13-00143" class="usa-link" aria-describedby="B2-medsci-13-00143">2</a>,<a href="#B3-medsci-13-00143" class="usa-link" aria-describedby="B3-medsci-13-00143">3</a>]. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases [<a href="#B4-medsci-13-00143" class="usa-link" aria-describedby="B4-medsci-13-00143">4</a>,<a href="#B5-medsci-13-00143" class="usa-link" aria-describedby="B5-medsci-13-00143">5</a>]. Despite recent advancements in treatment modalities, the prognosis for patients with advanced or metastatic NSCLC without driver mutations remains poor [<a href="#B6-medsci-13-00143" class="usa-link" aria-describedby="B6-medsci-13-00143">6</a>,<a href="#B7-medsci-13-00143" class="usa-link" aria-describedby="B7-medsci-13-00143">7</a>]. Effective treatment options remain limited, especially for patients with resistance to standard therapies, but immunotherapy has changed the treatment of NSCLC, first in second-line treatment, then in first-line treatment, and now also in neoadjuvant and perioperative treatment [<a href="#B6-medsci-13-00143" class="usa-link" aria-describedby="B6-medsci-13-00143">6</a>,<a href="#B8-medsci-13-00143" class="usa-link" aria-describedby="B8-medsci-13-00143">8</a>,<a href="#B9-medsci-13-00143" class="usa-link" aria-describedby="B9-medsci-13-00143">9</a>]. This study is timely due to the lack of clinical trial data over the past 5 years discussing the combination of nivolumab and bevacizumab in NSCLC patients without sensitizing gene mutations. There is increasing clinical interest in identifying therapies to modulate tumor responses, but further studies of efficacy are warranted. The advent of immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) have revolutionized cancer therapy due to their ability to utilize the body’s own immune system to identify and destroy cancer cells [<a href="#B10-medsci-13-00143" class="usa-link" aria-describedby="B10-medsci-13-00143">10</a>,<a href="#B11-medsci-13-00143" class="usa-link" aria-describedby="B11-medsci-13-00143">11</a>,<a href="#B12-medsci-13-00143" class="usa-link" aria-describedby="B12-medsci-13-00143">12</a>,<a href="#B13-medsci-13-00143" class="usa-link" aria-describedby="B13-medsci-13-00143">13</a>]. However, ICIs face challenges due to immune evasion mechanisms within the tumor microenvironment (TME) [<a href="#B14-medsci-13-00143" class="usa-link" aria-describedby="B14-medsci-13-00143">14</a>,<a href="#B15-medsci-13-00143" class="usa-link" aria-describedby="B15-medsci-13-00143">15</a>]. ICIs foster a strong immune response, which enables the immune system, particularly T cells within TME, to better recognize and attack tumor cells. However, resistance to ICIs poses significant challenges to effective treatment options [<a href="#B14-medsci-13-00143" class="usa-link" aria-describedby="B14-medsci-13-00143">14</a>,<a href="#B15-medsci-13-00143" class="usa-link" aria-describedby="B15-medsci-13-00143">15</a>]. Given the critical role of angiogenesis in tumor survival and its impact on tumor progression, it has become a promising focus of research. Current efforts aim to overcome resistance to immunotherapy in lung cancer by targeting angiogenic pathways and exploring therapeutic strategies that combine immune checkpoint inhibitors (ICIs) with anti-angiogenic agents to enhance treatment efficacy and improve patient outcomes [<a href="#B16-medsci-13-00143" class="usa-link" aria-describedby="B16-medsci-13-00143">16</a>,<a href="#B17-medsci-13-00143" class="usa-link" aria-describedby="B17-medsci-13-00143">17</a>,<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>].</p>
<p>Notably, ICIs such as nivolumab, a monoclonal antibody targeting the PD-1 receptor, has demonstrated significant efficacy in NSCLC by disrupting the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, thereby inhibiting the cellular immune response [<a href="#B19-medsci-13-00143" class="usa-link" aria-describedby="B19-medsci-13-00143">19</a>,<a href="#B20-medsci-13-00143" class="usa-link" aria-describedby="B20-medsci-13-00143">20</a>]. In addition, anti-angiogenic agents like bevacizumab, a targeted vascular endothelial growth factor (VEGF) inhibitor, have shown the ability to disrupt tumor vasculature, thereby inhibiting tumor growth and metastasis [<a href="#B21-medsci-13-00143" class="usa-link" aria-describedby="B21-medsci-13-00143">21</a>,<a href="#B22-medsci-13-00143" class="usa-link" aria-describedby="B22-medsci-13-00143">22</a>,<a href="#B23-medsci-13-00143" class="usa-link" aria-describedby="B23-medsci-13-00143">23</a>]. The idea for combining nivolumab with bevacizumab lies in their complementary mechanisms of action: while nivolumab stimulates T-cell-mediated immune responses, bevacizumab reduces angiogenesis, which can modify the TME to enhance immune cell infiltration and function [<a href="#B19-medsci-13-00143" class="usa-link" aria-describedby="B19-medsci-13-00143">19</a>,<a href="#B21-medsci-13-00143" class="usa-link" aria-describedby="B21-medsci-13-00143">21</a>,<a href="#B22-medsci-13-00143" class="usa-link" aria-describedby="B22-medsci-13-00143">22</a>,<a href="#B23-medsci-13-00143" class="usa-link" aria-describedby="B23-medsci-13-00143">23</a>]. This combination therapy has the potential to overcome resistance mechanisms that limit the efficacy of monotherapies, offering a more comprehensive approach to treating NSCLC. Clinical trials have provided encouraging results, showing improved PFS and OS in patients treated with the combination of nivolumab and bevacizumab, particularly when used alongside platinum-based chemotherapy [<a href="#B24-medsci-13-00143" class="usa-link" aria-describedby="B24-medsci-13-00143">24</a>,<a href="#B25-medsci-13-00143" class="usa-link" aria-describedby="B25-medsci-13-00143">25</a>,<a href="#B26-medsci-13-00143" class="usa-link" aria-describedby="B26-medsci-13-00143">26</a>,<a href="#B27-medsci-13-00143" class="usa-link" aria-describedby="B27-medsci-13-00143">27</a>]. The goal of this communication is to discuss the efficacy of targeting immune checkpoints and angiogenesis in patients without having sensitizing mutations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS proto-oncogene 1 (ROS1) oncogenes, and to highlight the exploration of combination therapy for NSCLC treatment without utilizing predictive biomarker responses.</p></section><section id="sec2-medsci-13-00143"><h2 class="pmc_sec_title">2. Mechanisms of Action of Nivolumab and Bevacizumab</h2>
<p>Nivolumab (OPDIVO) is an FDA-approved drug available as a single-use injection for a variety of human malignancies, including NSCLC, small cell lung cancer (SCLC), pleural mesothelioma, melanoma, squamous cell carcinoma of the head and neck, renal cell carcinoma, urothelial carcinoma, hepatocellular carcinoma, colorectal cancer, Hodgkin lymphoma, and esophageal squamous cell carcinoma [<a href="#B19-medsci-13-00143" class="usa-link" aria-describedby="B19-medsci-13-00143">19</a>,<a href="#B28-medsci-13-00143" class="usa-link" aria-describedby="B28-medsci-13-00143">28</a>]. Nivolumab is a human IgG4 monoclonal antibody checkpoint inhibitor that binds to programmed death-1 receptors (PD-1) expressed on activated T-cells. When PD-1 binds to its ligands, PD-L1 and PD-L2, which are expressed on antigen presenting cells (APCs) and other cells, inhibitory signals are sent to T-cells. This dampens the immune response, helping to maintain tolerance and prevent tissue damage from excessive immune activity [<a href="#B19-medsci-13-00143" class="usa-link" aria-describedby="B19-medsci-13-00143">19</a>]. However, abnormal PD-L1 expression by tumor cells utilize this pathway to evade proper immune detection [<a href="#B19-medsci-13-00143" class="usa-link" aria-describedby="B19-medsci-13-00143">19</a>]. When PD-L1 on tumor cells binds to PD-1 on T-cells, the lymphocytes become deactivated and allow the tumor cells to evade immune recognition and continue proliferation unchecked. Nivolumab blocks the interaction between PD-1 and PD-L1/PD-L2 to prevent the inhibitory signal from being transmitted, allowing T-cells to remain active and recognize and destroy tumor cells [<a href="#B19-medsci-13-00143" class="usa-link" aria-describedby="B19-medsci-13-00143">19</a>,<a href="#B29-medsci-13-00143" class="usa-link" aria-describedby="B29-medsci-13-00143">29</a>,<a href="#B30-medsci-13-00143" class="usa-link" aria-describedby="B30-medsci-13-00143">30</a>].</p>
<p>Bevacizumab (AVASTIN) was first approved by the FDA in 2004 as an intravenous (IV) infusion and is currently approved for metastatic colorectal cancer, non-squamous NSCLC, glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent, or metastatic carcinoma of the cervix [<a href="#B31-medsci-13-00143" class="usa-link" aria-describedby="B31-medsci-13-00143">31</a>]. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to VEGF to inhibit its binding to the cell surface VEGF receptors for both the tumor cells as well as the local healthy cells [<a href="#B31-medsci-13-00143" class="usa-link" aria-describedby="B31-medsci-13-00143">31</a>]. This creates two different mechanisms by which bevacizumab can combat cancer cells. By blocking VEGF from binding to healthy endothelial cells, it can effectively block the signaling for angiogenesis and disrupt the creation of blood vessels needed by the tumor cells [<a href="#B17-medsci-13-00143" class="usa-link" aria-describedby="B17-medsci-13-00143">17</a>,<a href="#B21-medsci-13-00143" class="usa-link" aria-describedby="B21-medsci-13-00143">21</a>,<a href="#B22-medsci-13-00143" class="usa-link" aria-describedby="B22-medsci-13-00143">22</a>,<a href="#B32-medsci-13-00143" class="usa-link" aria-describedby="B32-medsci-13-00143">32</a>,<a href="#B33-medsci-13-00143" class="usa-link" aria-describedby="B33-medsci-13-00143">33</a>]. When VEGF is blocked from binding to the receptors directly on the tumor cells, it can inhibit the signaling for cell proliferation and survival. VEGF is also an important immunomodulator of TME. The mechanism of actions of nivolumab and bevacizumab is depicted in <a href="#medsci-13-00143-f001" class="usa-link">Figure 1</a>.</p>
<figure class="fig xbox font-sm" id="medsci-13-00143-f001"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371936_medsci-13-00143-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19d4/12371936/c03e1fef3015/medsci-13-00143-g001.jpg" loading="lazy" height="794" width="690" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/medsci-13-00143-f001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mechanisms of action of nivolumab and bevacizumab.</p></figcaption></figure><p>When used in combination, nivolumab and bevacizumab offer complimentary mechanisms. Despite this synergy, resistance to the combination may still arise. VEGF inhibitors can lead to hypoxia driven upregulation of other pro-angiogenic pathways. Similarly, not all tumors respond to PD-1 blockage due to antigen presentation defects.</p></section><section id="sec3-medsci-13-00143"><h2 class="pmc_sec_title">3. Mechanism of Resistance and Adverse Reactions of Nivolumab and Bevacizumab</h2>
<p>Patients treated with immune checkpoint therapy such as nivolumab can acquire resistance to the drug through mechanisms that are not very well understood [<a href="#B27-medsci-13-00143" class="usa-link" aria-describedby="B27-medsci-13-00143">27</a>]. Many theorize that resistance could be multifactorial, including ideas such as the TME including various factors and cell types such as regulatory T cells (Tregs), myeloid-derived suppressive cells (MDSCs), tumor-associated macrophages (TAMs), and immature dendritic cells (imDC) [<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>]. Low or variable PD-L1 expression in NSCLC tumors and other associated mechanisms might not respond well to nivolumab [<a href="#B27-medsci-13-00143" class="usa-link" aria-describedby="B27-medsci-13-00143">27</a>]. Certain mutations in genes such as rearranged during transfection (RET) or human epidermal growth factor receptor 2 (HER2) can also reduce the expression of PD-L1, thus reducing the effectiveness of nivolumab [<a href="#B27-medsci-13-00143" class="usa-link" aria-describedby="B27-medsci-13-00143">27</a>]. Additionally, low tumor mutation burden (TMB) can increase the likelihood of nivolumab and other PD-1 inhibitors being an ineffective treatment option because these tumors are unable to elicit a strong immune response to PD-1 inhibiting drugs [<a href="#B10-medsci-13-00143" class="usa-link" aria-describedby="B10-medsci-13-00143">10</a>,<a href="#B34-medsci-13-00143" class="usa-link" aria-describedby="B34-medsci-13-00143">34</a>]. Other mechanisms of resistance involve insufficient antigen recognition by T-cells and other downstream effects of issues in the T-cell activation process [<a href="#B35-medsci-13-00143" class="usa-link" aria-describedby="B35-medsci-13-00143">35</a>]. Additional factors that affect the resistance of ICIs such as nivolumab include EGFR mutations and ALK alterations [<a href="#B36-medsci-13-00143" class="usa-link" aria-describedby="B36-medsci-13-00143">36</a>]. Moreover, associated adverse reactions are other potential challenges to effective treatments. The FDA cites several adverse reactions to nivolumab as a single agent as well as in combination with ipilimumab, platinum chemotherapy, cabozantinib and with fluoropyrimidine [<a href="#B28-medsci-13-00143" class="usa-link" aria-describedby="B28-medsci-13-00143">28</a>]. For example, nivolumab can cause severe infusion-related reactions, which have been reported in &lt;1.0% of patients in clinical trials [<a href="#B28-medsci-13-00143" class="usa-link" aria-describedby="B28-medsci-13-00143">28</a>]. Fatigue, musculoskeletal pain, diarrhea, nausea, rash, pruritus, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, upper respiratory tract infection, arthralgia, pyrexia, headache, abdominal pain, vomiting, and urinary tract infection are other adverse effects of nivolumab [<a href="#B28-medsci-13-00143" class="usa-link" aria-describedby="B28-medsci-13-00143">28</a>].</p>
<p>While bevacizumab impacts tumor proliferation in multiple ways, patients receiving bevacizumab have shown acquired resistance to the treatment [<a href="#B32-medsci-13-00143" class="usa-link" aria-describedby="B32-medsci-13-00143">32</a>]. The specific mechanisms of resistance of bevacizumab are still being studied; however, there are several factors that are thought to play a role in the resistance [<a href="#B32-medsci-13-00143" class="usa-link" aria-describedby="B32-medsci-13-00143">32</a>,<a href="#B33-medsci-13-00143" class="usa-link" aria-describedby="B33-medsci-13-00143">33</a>]. First, while VEGF is a powerful angiogenic signaling molecule, it is not the only signal for angiogenesis, and it is thought that the tumor cells can upregulate other angiogenic signaling pathways, such as hypoxia-inducible factor-1 alpha (HIF-1α) in the presence of bevacizumab [<a href="#B32-medsci-13-00143" class="usa-link" aria-describedby="B32-medsci-13-00143">32</a>]. Second, the TME seems to broadly impact the efficacy of chemotherapeutic agents and bevacizumab. It seems hypoxia is the most significant factor in the TME, which is consequently increased by blocking angiogenesis with a VEGF inhibitor [<a href="#B32-medsci-13-00143" class="usa-link" aria-describedby="B32-medsci-13-00143">32</a>,<a href="#B35-medsci-13-00143" class="usa-link" aria-describedby="B35-medsci-13-00143">35</a>,<a href="#B37-medsci-13-00143" class="usa-link" aria-describedby="B37-medsci-13-00143">37</a>]. In fact, it is documented that the hypoxia induced by an angiogenesis inhibitor has the potential to worsen tumor invasiveness and metastasis [<a href="#B37-medsci-13-00143" class="usa-link" aria-describedby="B37-medsci-13-00143">37</a>]. Notably, there are several implications of hypoxia in the TME that can lead to tumor survival, but among them is the hypoxia’s recruitment of myeloid cells into the TME that ultimately facilitate an immunosuppressive microenvironment and a weakened antitumor response [<a href="#B32-medsci-13-00143" class="usa-link" aria-describedby="B32-medsci-13-00143">32</a>]. Moreover, induction of hypoxic condition mediated through VEGF inhibitors reduces the recruitment of suppressive cells into the TME to improve the efficacy of immunotherapies [<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>,<a href="#B27-medsci-13-00143" class="usa-link" aria-describedby="B27-medsci-13-00143">27</a>]. Additionally, adverse reactions to bevacizumab are also potential challenges to effective treatment. Bevacizumab is also associated with several adverse reactions that occurred in greater than 10% of patients taking the medication. These adverse reactions include epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, and exfoliative dermatitis [<a href="#B31-medsci-13-00143" class="usa-link" aria-describedby="B31-medsci-13-00143">31</a>]. According to the FDA, bevacizumab was discontinued in 8.4–21% of patients across all studies because of these reactions. Of note, the maximum dose tested in humans was 20 mg/kg IV, and nine of the sixteen patients developed a headache, three of which experienced severe headaches [<a href="#B31-medsci-13-00143" class="usa-link" aria-describedby="B31-medsci-13-00143">31</a>].</p></section><section id="sec4-medsci-13-00143"><h2 class="pmc_sec_title">4. Studies of Nivolumab and Bevacizumab Combination with or Without Other Agents</h2>
<p>A focused literature search was conducted using PubMed for articles published between 2020 and 2024. Keywords included ‘non-small cell lung cancer,’ ‘nivolumab,’ ‘bevacizumab,’ ‘immune checkpoint inhibitors,’ and ‘anti-angiogenesis.’ Only English-language articles and clinical trials involving human subjects were included, yielding the four studies discussed below. The two drugs, nivolumab and bevacizumab, have been studied in clinical trials in addition to therapies such as platinum chemotherapy, cell cycle inhibitor chemotherapy, and DNA synthesis inhibitor chemotherapy [<a href="#B24-medsci-13-00143" class="usa-link" aria-describedby="B24-medsci-13-00143">24</a>,<a href="#B25-medsci-13-00143" class="usa-link" aria-describedby="B25-medsci-13-00143">25</a>,<a href="#B26-medsci-13-00143" class="usa-link" aria-describedby="B26-medsci-13-00143">26</a>,<a href="#B38-medsci-13-00143" class="usa-link" aria-describedby="B38-medsci-13-00143">38</a>]. There is a gap in our knowledge of how nivolumab and bevacizumab combination without additional chemotherapy interact as a potential therapy for treatment in NSCLC. The summary of clinical studies with a combination of nivolumab and bevacizumab is given in <a href="#medsci-13-00143-t001" class="usa-link">Table 1</a>.</p>
<section class="tw xbox font-sm" id="medsci-13-00143-t001"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Evidence of nivolumab and bevacizumab studies with or without other therapeutic agents for NSCLC is summarized.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient<br>Population</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study<br>Design</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intervention</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Control</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primary<br>Endpoint</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Results</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Treatment-<br>naïve stage HIB/IV<br>NSCLC</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Randomized<br>1:1 trial</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Nivolumab<br>with<br>bevacizumab<br> + platinum-<br>based chemo</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Placebo<br> + chemo</td>
<td align="center" valign="middle" rowspan="1" colspan="1">OS</td>
<td align="center" valign="middle" rowspan="1" colspan="1">OS: 30.8 vs.<br>24.7 months<br>(HR 0.74)<br>CI: 0.58–0.94</td>
<td align="center" valign="middle" rowspan="1" colspan="1">[<a href="#B24-medsci-13-00143" class="usa-link" aria-describedby="B24-medsci-13-00143">24</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Treatment-<br>naïve stage IIIB/IV<br>NSCLC</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Randomized,<br>double-<br>blind, 1:1 trial</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Nivolumab<br>with<br>bevacizumab,<br>paclitaxel<br> + platinum-based chemo</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Placebo<br> + chemo</td>
<td align="center" valign="middle" rowspan="1" colspan="1">PFS</td>
<td align="center" valign="middle" rowspan="1" colspan="1">PFS: 12.1 vs.<br>8.1 months<br>(HR 0.56)<br>CI: 0.43–0.71</td>
<td align="center" valign="middle" rowspan="1" colspan="1">[<a href="#B25-medsci-13-00143" class="usa-link" aria-describedby="B25-medsci-13-00143">25</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Japanese<br>patients<br>with<br>NSCLC</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Phase Ib</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Nivolumab<br>with<br>bevacizumab,<br>paclitaxel<br> + platinum-based chemo</td>
<td align="center" valign="middle" rowspan="1" colspan="1">None</td>
<td align="center" valign="middle" rowspan="1" colspan="1">PFS and OS</td>
<td align="center" valign="middle" rowspan="1" colspan="1">PFS:<br>40.7 months,<br>OS:<br>28.5 months<br>CI: not reported</td>
<td align="center" valign="middle" rowspan="1" colspan="1">[<a href="#B26-medsci-13-00143" class="usa-link" aria-describedby="B26-medsci-13-00143">26</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Meta-<br>analysis of<br>phase III<br>clinical trials</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab + ipilimumab<br>with<br>bevacizumab</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemo<br>alone</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OS</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved OS in EGFR/<br>ALK mutated patients<br>CI: not reported</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B38-medsci-13-00143" class="usa-link" aria-describedby="B38-medsci-13-00143">38</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/medsci-13-00143-t001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>One clinical trial assessed the approach of combining nivolumab or placebo with bevacizumab plus platinum-based chemotherapy for treatment of NSCLC patients without driver mutations in ALK, EGFR, or ROS1, evaluated the safety and effectiveness in the treatment plan [<a href="#B24-medsci-13-00143" class="usa-link" aria-describedby="B24-medsci-13-00143">24</a>]. The 550 patients were randomized. At the time of the analysis (minimum follow-up: 19.4 months), the median overall survival (OS) was longer in the nivolumab arm than in the placebo arm (30.8 vs. 24.7 months; hazard ratio 0.74; 95% confidence interval 0.58–0.94). The 12-month OS rates were 81.3% vs. 76.3% in the nivolumab vs. placebo arms, respectively. The respective 18-month OS rates were 69.0% vs. 61.9%. This treatment regimen was identical to their previous clinical trial and concluded that nivolumab in combination with platinum chemotherapy and bevacizumab demonstrated a longer OS compared to the placebo combination [<a href="#B24-medsci-13-00143" class="usa-link" aria-describedby="B24-medsci-13-00143">24</a>]. This study did not mention adverse events in their conclusion.</p>
<p>In an additional study, nivolumab was assessed with carboplatin, paclitaxel, and bevacizumab in NSCLC patients with stage IIIB/IV or recurrent NSCLC without sensitizing EGFR, ALK, or ROS1 alterations [<a href="#B25-medsci-13-00143" class="usa-link" aria-describedby="B25-medsci-13-00143">25</a>]. This study initially used carboplatin, paclitaxel, and bevacizumab every 3 weeks for up to six cycles and had maintenance therapy using nivolumab/placebo with bevacizumab [<a href="#B25-medsci-13-00143" class="usa-link" aria-describedby="B25-medsci-13-00143">25</a>]. This study included a cohort of 550 patients, 273 received the nivolumab and 275 received placebo combinations, respectively. With a median follow up of 13.7 months, the Independent Regulatory Review (IRRC)-assessed that the median progression free survival (PFS) was significantly longer in the nivolumab arm than in the placebo arm (12.1 versus 8.1 months; hazard ratio 0.56; 96.4% confidence interval 0.43–0.71). The PFS benefit was observed across all patients with any PD-L1 expression levels, including PD-L1-negative patients. This study concluded that nivolumab/bevacizumab with cytotoxic chemotherapy should be considered as it demonstrated significant improvement in PFS [<a href="#B25-medsci-13-00143" class="usa-link" aria-describedby="B25-medsci-13-00143">25</a>]. The incidence of treatment related adverse events was comparable between the control and treatment groups. Treatment related events leading to death were observed in five and four patients in the treatment and placebo group, respectively [<a href="#B25-medsci-13-00143" class="usa-link" aria-describedby="B25-medsci-13-00143">25</a>].</p>
<p>An additional clinical trial assessed nivolumab efficacy in different combinations of chemotherapeutic agents for NSCLC without targetable oncogenes, respectively [<a href="#B26-medsci-13-00143" class="usa-link" aria-describedby="B26-medsci-13-00143">26</a>]. The patients were divided into four treatment arms. Arm A includes four cycles of cisplatin and gemcitabine; arm B includes four cycles of cisplatin and pemetrexed followed by pemetrexed maintenance therapy; arm C includes four to six cycles of carboplatin, paclitaxel, and bevacizumab followed by bevacizumab; and arm D includes docetaxel. In this trial, minimum follow-up period was 57.9 months. Median PFS was 6.3 (0.7+–47.8), 11.8 (1.4–65.1+), 40.7 (5.3–60.8+), and 3.2 (1.9–10.9) months, and 5-year PFS was observed in 0/6, 1/6, 1/6, and 0/6 patients in arms A, B, C, and D, respectively. Median OS was 13.2 (11.0–55.4), 28.5 (14.6–66.2+), not reached (24.2–67.4+), and 12.5 (9.8–16.9) months, and the number of patients surviving 5 years were 0/6, 1/6, 4/6, and 0/6 in arms A, B, C, and D, respectively. This trial concluded that the nivolumab/carboplatin/paclitaxel/bevacizumab therapy combination showed both tolerability and 5-year PFS and OS [<a href="#B26-medsci-13-00143" class="usa-link" aria-describedby="B26-medsci-13-00143">26</a>]. No unexpected severe adverse events or treatment-related deaths occurred in this trial [<a href="#B26-medsci-13-00143" class="usa-link" aria-describedby="B26-medsci-13-00143">26</a>].</p>
<p>A systematic review assessed checkpoint inhibitor combinations, including pembrolizumab, atezolizumab, and atezolizumab/bevacizumab for NSCLC treatment. This review showed significantly improved OS compared with controls in patients with advanced NSCLC without EGFR/ALK mutations [<a href="#B38-medsci-13-00143" class="usa-link" aria-describedby="B38-medsci-13-00143">38</a>]. Two trials reported outcomes for squamous NSCLC, with pembrolizumab–chemotherapy reporting significantly improved (OS) compared with chemotherapy. Of note, the combination of nivolumab–ipilimumab failed to improve OS [<a href="#B38-medsci-13-00143" class="usa-link" aria-describedby="B38-medsci-13-00143">38</a>]. Outcomes for atezolizumab–bevacizumab–chemotherapy in EGFR+/ALK+ patients are promising and require further exploration. The results of this review indicated that pembrolizumab (PD-1 inhibitor) improved OS, and the atezolizumab/bevacizumab combination therapy for EGFR+/ALK+ patients requires additional studies [<a href="#B38-medsci-13-00143" class="usa-link" aria-describedby="B38-medsci-13-00143">38</a>].</p>
<p>While these studies collectively demonstrate the potential of combining ICIs and anti-angiogenesis agents to benefit patients with NSCLC, there are important limitations and discrepancies. Variations in trial design, chemotherapy regimens, follow-up periods, and reporting of adverse events limit direct comparison. This highlights the need for standardized study designs and biomarker-driven strategies in future studies.</p></section><section id="sec5-medsci-13-00143"><h2 class="pmc_sec_title">5. Potential of Other ICIs and Anti-Angiogenic Therapies for NSCLC</h2>
<p>In addition to the combination of nivolumab and bevacizumab, several other ICIs have been studied in combination with anti-angiogenic therapies for the treatment of NSCLC [<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>,<a href="#B39-medsci-13-00143" class="usa-link" aria-describedby="B39-medsci-13-00143">39</a>]. The other considerable therapies are listed in <a href="#medsci-13-00143-t002" class="usa-link">Table 2</a>.</p>
<section class="tw xbox font-sm" id="medsci-13-00143-t002"><h3 class="obj_head">Table 2.</h3>
<div class="caption p"><p>Evidence from other ICI and anti-angiogenic-based approaches for NSCLC is summarized.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient<br>Population</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intervention</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Control</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primary<br>Endpoint</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Results</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic non-squamous<br>NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III clinical trial</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bevacizumab +<br>Carboplatin +<br>Paclitaxel</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atezolizumab + Bevacizumab <br>+ Carboplatin<br>+ Paclitaxel</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PFS and OS</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median PFS: 8.3 months<br>(Intervention) vs. 6.8 months (Control) (HR:<br>0.59, <em>p</em> &lt; 0.0001);<br>Median OS: 19.2 months<br>(Intervention) vs. 14.7 months (Control) (HR:<br>0.78, <em>p</em> = 0.02)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic<br>NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical and clinical studies</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab<br>+ Lenvatinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modulation of TME</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lenvatinib may decrease<br>TAMs and Tregs,<br>improving ICI efficacy (<em>p</em> &lt; 0.01)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B39-medsci-13-00143" class="usa-link" aria-describedby="B39-medsci-13-00143">39</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic<br>NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Open-label phase la/b trial</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab<br>+ Ramucirumab</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PFS and OS</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median PFS: 9.3 months;<br>12-month and 18-month<br>PFS: 45%;<br>12-month and 18-month<br>OS: 73% and 64%<br>Respectively<br>(<em>p</em> value not reported)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B40-medsci-13-00143" class="usa-link" aria-describedby="B40-medsci-13-00143">40</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/medsci-13-00143-t002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>Atezolizumab, an anti-PD-L1 antibody, has been evaluated in combination with bevacizumab in a phase III clinical trial [<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>]. This study demonstrated that the combination, along with chemotherapy, improved PFS and OS in patients with metastatic non-squamous NSCLC [<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>]. The median PFS of the group in combination with atezolizumab, carboplatin, paclitaxel, and bevacizumab was 8.3 months, and the carboplatin, paclitaxel, and bevacizumab group PFS was 6.8 months (HR: 0.59). The median OS was 19.2 months for the first group, and 14.7 months for the second 31 group (HR: 0.78) [<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>]. The anti-angiogenic effects of bevacizumab are thought to enhance the immune response elicited by atezolizumab. The incidence of treatment-related adverse events was 25.4% for the atezolizumab, carboplatin, paclitaxel, and bevacizumab group and 19.3% for the bevacizumab, carboplatin, and paclitaxel group. However, 77.4% of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) patients had grade 1–2 AEs [<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>].</p>
<p>Pembrolizumab has been combined with lenvatinib, a tyrosine kinase inhibitor (TKI) that includes anti-angiogenic properties such as targeting VEGF and fibroblast growth factor (FGF) [<a href="#B39-medsci-13-00143" class="usa-link" aria-describedby="B39-medsci-13-00143">39</a>]. This combination has shown potential in enhancing anti-tumor activity by modulating the TME [<a href="#B39-medsci-13-00143" class="usa-link" aria-describedby="B39-medsci-13-00143">39</a>]. In addition, preclinical studies suggest that lenvatinib can decrease TAMs and Tregs, thereby improving the efficacy of ICIs [<a href="#B39-medsci-13-00143" class="usa-link" aria-describedby="B39-medsci-13-00143">39</a>,<a href="#B40-medsci-13-00143" class="usa-link" aria-describedby="B40-medsci-13-00143">40</a>].</p>
<p>Pembrolizumab has also been combined with ramucirumab, an anti-VEGFR-2 antibody [<a href="#B40-medsci-13-00143" class="usa-link" aria-describedby="B40-medsci-13-00143">40</a>]. An open-label phase 1a/b trial found median PFS at 9.3 months, while 12-month and 18-month PFS were each 45%. Median OS was not reached, but the 12-month and 18-month OS rates were 73% and 64%, respectively [<a href="#B40-medsci-13-00143" class="usa-link" aria-describedby="B40-medsci-13-00143">40</a>]. The rationale is that inhibiting VEGFR-2 can normalize tumor vasculature and reduce immunosuppressive cells, thereby potentiating the effects of pembrolizumab [<a href="#B40-medsci-13-00143" class="usa-link" aria-describedby="B40-medsci-13-00143">40</a>]. Adverse effects associated with this therapy were fatigue and myocardial infarction in 7% of 31 patients [<a href="#B18-medsci-13-00143" class="usa-link" aria-describedby="B18-medsci-13-00143">18</a>,<a href="#B40-medsci-13-00143" class="usa-link" aria-describedby="B40-medsci-13-00143">40</a>].</p></section><section id="sec6-medsci-13-00143"><h2 class="pmc_sec_title">6. Conclusions and Future Perspectives</h2>
<p>NSCLC has a variety of treatment options for patients lacking EGFR, ALK, or ROS1 mutations. The data demonstrated that nivolumab in combination with bevacizumab and platinum-based chemotherapy provide promising results in improving PFS and OS in patients with NSCLC. While few clinical trials demonstrated the beneficial effects of these immunotherapies, further research is needed to assess the efficacy of combination immunotherapy in patients lacking gene mutations. In addition, while biomarkers aid in the diagnosis of disease pathology, identifying biomarkers that predict response to combination therapy remains a challenge. Moreover, lack of accuracy in biomarkers can lead to unnecessary pharmacological interventions and potential adverse effects which should be monitored carefully in patients receiving treatment. While biomarkers such as PD-L1 expression are useful in predicting nivolumab efficacy, they are not reliable predictors of adverse events. Although nivolumab generally has a favorable safety profile, further research is needed to identify biomarkers that can guide both therapeutic response and toxicity risk. Bevacizumab has been reported to have adverse reactions in greater than 10% of patients. Taken together, nivolumab and bevacizumab should be evaluated with careful consideration with other therapeutic agents for the treatment of NSCLC. Additionally, current clinical data on ICIs and anti-angiogenesis combinations in NSCLC are currently limited by small sample sizes and short follow-up periods and should aim to incorporate more diverse patient populations. Emphasis should be placed on longitudinal sampling to monitor changes in the TME and immune system functionality. Future research should focus on developing more comprehensive biomarker panels that combine immune markers, angiogenesis markers, and characteristics of the TME. Gaining a better understanding of resistance mechanisms could help inform the design of combination therapies and improve how treatments are timed to extend patient response.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>The authors would like to acknowledge BioRender software (<a href="https://www.biorender.com/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.biorender.com/</a>) for generating the figure.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<section class="tw xbox font-sm" id="array1"><div class="tbl-box p" tabindex="0"><table class="content">
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Non-small cell lung cancer</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">ICIs</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Immune checkpoint inhibitors</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">PFS</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Progression free survival</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">OS</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Overall survival</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">EGFR</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Epidermal growth factor receptor</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">ALK</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Anaplastic lymphoma kinase</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">ROS1</td>
<td align="left" valign="middle" rowspan="1" colspan="1">ROS proto-oncogene 1</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">PD-1</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Programmed death-1</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">PD-L1</td>
<td align="left" valign="middle" rowspan="1" colspan="1">PD-ligand 1</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">CTLA-4</td>
<td align="left" valign="middle" rowspan="1" colspan="1">cytotoxic T lymphocyte antigen 4</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">TME</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Tumor microenvironment</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">VEGF</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Vascular endothelial growth factor</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">APC</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Antigen presenting cells</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">Tregs</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Regulatory T cells</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">MDSCs</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Myeloid-derived suppressive cells</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">TAMs</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Tumor-associated macrophages</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">imDC</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Immature dendritic cells</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">RET</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Rearranged during transfection</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">TMB</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Tumor mutation burden</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">HIF-1α</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Hypoxia-inducible factor-1 alpha</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">IRRC</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Independent Regulatory Review</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">FGF</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Fibroblast growth factor</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">TKI</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Tyrosine kinase inhibitor</td>
</tr>
</table></div>
<div class="p text-right font-secondary"><a href="table/array1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="notes1"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>Conceptualization, T.B. and R.P.S.; BioRender software, A.T.; validation, T.B., A.T. and R.P.S.; formal analysis, T.B.; data curation, T.B.; writing—original draft preparation, T.B.; writing—review and editing, T.B., A.T. and R.P.S.; visualization, A.T.; supervision, R.P.S.; project administration, R.P.S. All authors have read and agreed to the published version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Institutional Review Board Statement</h2>
<p>Not applicable.</p></section><section id="notes3"><h2 class="pmc_sec_title">Informed Consent Statement</h2>
<p>Not applicable.</p></section><section id="notes4"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>No new data were created or analyzed in this study.</p></section><section id="notes5"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest.</p></section><section id="funding-statement1" lang="en"><h2 class="pmc_sec_title">Funding Statement</h2>
<p>The financial support from the NIH R21 Grant ES033806 (to R.P.S.) is greatly appreciated.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1"><p><strong>Disclaimer/Publisher’s Note:</strong> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1-medsci-13-00143">
<span class="label">1.</span><cite>Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708.</cite> [<a href="https://doi.org/10.3322/caac.21708" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35020204/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J.%20Clin.&amp;title=Cancer%20statistics,%202022&amp;author=R.L.%20Siegel&amp;author=K.D.%20Miller&amp;author=H.E.%20Fuchs&amp;author=A.%20Jemal&amp;volume=72&amp;publication_year=2022&amp;pages=7-33&amp;pmid=35020204&amp;doi=10.3322/caac.21708&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2-medsci-13-00143">
<span class="label">2.</span><cite>Lahiri A., Maji A., Potdar P.D., Singh N., Parikh P., Bisht B., Mukherjee A., Paul M.K. Lung cancer immunotherapy: Progress, pitfalls, and promises. Mol. Cancer. 2023;22:40. doi: 10.1186/s12943-023-01740-y.</cite> [<a href="https://doi.org/10.1186/s12943-023-01740-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9942077/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36810079/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cancer&amp;title=Lung%20cancer%20immunotherapy:%20Progress,%20pitfalls,%20and%20promises&amp;author=A.%20Lahiri&amp;author=A.%20Maji&amp;author=P.D.%20Potdar&amp;author=N.%20Singh&amp;author=P.%20Parikh&amp;volume=22&amp;publication_year=2023&amp;pages=40&amp;pmid=36810079&amp;doi=10.1186/s12943-023-01740-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3-medsci-13-00143">
<span class="label">3.</span><cite>Fois S.S., Paliogiannis P., Zinellu A., Fois A.G., Cossu A., Palmieri G. Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2021;22:612.  doi: 10.3390/ijms22020612.</cite> [<a href="https://doi.org/10.3390/ijms22020612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7827915/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33435440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=Molecular%20Epidemiology%20of%20the%20Main%20Druggable%20Genetic%20Alterations%20in%20Non-Small%20Cell%20Lung%20Cancer&amp;author=S.S.%20Fois&amp;author=P.%20Paliogiannis&amp;author=A.%20Zinellu&amp;author=A.G.%20Fois&amp;author=A.%20Cossu&amp;volume=22&amp;publication_year=2021&amp;pages=612&amp;pmid=33435440&amp;doi=10.3390/ijms22020612&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4-medsci-13-00143">
<span class="label">4.</span><cite>Basumallik N., Agarwal M. Small Cell Lung Cancer. StatPearls, 10 July 2023.  [(accessed on 15 March 2025)]; Available online:  <a href="https://www.ncbi.nlm.nih.gov/books/NBK482458/" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/books/NBK482458/</a></cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/29494065/" class="usa-link">PubMed</a>]</li>
<li id="B5-medsci-13-00143">
<span class="label">5.</span><cite>Zhu J., Li R., Tiselius E., Roudi R., Teghararian O., Suo C., Song H. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst. Rev. 2017;12:CD011300. doi: 10.1002/14651858.CD011300.pub2.</cite> [<a href="https://doi.org/10.1002/14651858.CD011300.pub2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6486009/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29247502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cochrane%20Database%20Syst.%20Rev.&amp;title=Immunotherapy%20(excluding%20checkpoint%20inhibitors)%20for%20stage%20I%20to%20III%20non-small%20cell%20lung%20cancer%20treated%20with%20surgery%20or%20radiotherapy%20with%20curative%20intent&amp;author=J.%20Zhu&amp;author=R.%20Li&amp;author=E.%20Tiselius&amp;author=R.%20Roudi&amp;author=O.%20Teghararian&amp;volume=12&amp;publication_year=2017&amp;pages=CD011300&amp;pmid=29247502&amp;doi=10.1002/14651858.CD011300.pub2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6-medsci-13-00143">
<span class="label">6.</span><cite>Miao D., Zhao J., Han Y., Zhou J., Li X., Zhang T., Li W., Xia Y. Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun. 2024;44:23–46. doi: 10.1002/cac2.12505.</cite> [<a href="https://doi.org/10.1002/cac2.12505" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10794016/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37985191/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Commun.&amp;title=Management%20of%20locally%20advanced%20non-small%20cell%20lung%20cancer:%20State%20of%20the%20art%20and%20future%20directions&amp;author=D.%20Miao&amp;author=J.%20Zhao&amp;author=Y.%20Han&amp;author=J.%20Zhou&amp;author=X.%20Li&amp;volume=44&amp;publication_year=2024&amp;pages=23-46&amp;pmid=37985191&amp;doi=10.1002/cac2.12505&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B7-medsci-13-00143">
<span class="label">7.</span><cite>Dafni U., Tsourti Z., Vervita K., Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer. 2019;134:127–140. doi: 10.1016/j.lungcan.2019.05.029.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2019.05.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31319971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Immune%20checkpoint%20inhibitors,%20alone%20or%20in%20combination%20with%20chemotherapy,%20as%20first-line%20treatment%20for%20advanced%20non-small%20cell%20lung%20cancer.%20A%20systematic%20review%20and%20network%20meta-analysis&amp;author=U.%20Dafni&amp;author=Z.%20Tsourti&amp;author=K.%20Vervita&amp;author=S.%20Peters&amp;volume=134&amp;publication_year=2019&amp;pages=127-140&amp;pmid=31319971&amp;doi=10.1016/j.lungcan.2019.05.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8-medsci-13-00143">
<span class="label">8.</span><cite>Muthusamy B., Patil P.D., Pennell N.A. Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer. J. Natl. Compr. Cancer Netw. 2022;20:953–961. doi: 10.6004/jnccn.2022.7021.</cite> [<a href="https://doi.org/10.6004/jnccn.2022.7021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35948038/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Natl.%20Compr.%20Cancer%20Netw.&amp;title=Perioperative%20Systemic%20Therapy%20for%20Resectable%20Non-Small%20Cell%20Lung%20Cancer&amp;author=B.%20Muthusamy&amp;author=P.D.%20Patil&amp;author=N.A.%20Pennell&amp;volume=20&amp;publication_year=2022&amp;pages=953-961&amp;pmid=35948038&amp;doi=10.6004/jnccn.2022.7021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9-medsci-13-00143">
<span class="label">9.</span><cite>Uprety D., West H.J. Perioperative Therapy for Resectable Non–Small-Cell Lung Cancer: Weighing Options for the Present and Future. JCO Oncol. Pract. 2023;19:403–409. doi: 10.1200/OP.23.00014.</cite> [<a href="https://doi.org/10.1200/OP.23.00014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37023371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Oncol.%20Pract.&amp;title=Perioperative%20Therapy%20for%20Resectable%20Non%E2%80%93Small-Cell%20Lung%20Cancer:%20Weighing%20Options%20for%20the%20Present%20and%20Future&amp;author=D.%20Uprety&amp;author=H.J.%20West&amp;volume=19&amp;publication_year=2023&amp;pages=403-409&amp;pmid=37023371&amp;doi=10.1200/OP.23.00014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B10-medsci-13-00143">
<span class="label">10.</span><cite>Ricciuti B., Wang X., Alessi J.V., Rizvi H., Mahadevan N.R., Li Y.Y., Polio A., Lindsay J., Umeton R., Sinha R., et al.  Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol. 2022;8:1160–1168. doi: 10.1001/jamaoncol.2022.1981.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2022.1981" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9204620/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35708671/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol.&amp;title=Association%20of%20High%20Tumor%20Mutation%20Burden%20in%20Non%E2%80%93Small%20Cell%20Lung%20Cancers%20with%20Increased%20Immune%20Infiltration%20and%20Improved%20Clinical%20Outcomes%20of%20PD-L1%20Blockade%20Across%20PD-L1%20Expression%20Levels&amp;author=B.%20Ricciuti&amp;author=X.%20Wang&amp;author=J.V.%20Alessi&amp;author=H.%20Rizvi&amp;author=N.R.%20Mahadevan&amp;volume=8&amp;publication_year=2022&amp;pages=1160-1168&amp;pmid=35708671&amp;doi=10.1001/jamaoncol.2022.1981&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B11-medsci-13-00143">
<span class="label">11.</span><cite>Wu K., Yi M., Qin S., Chu Q., Zheng X., Wu K. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: A meta-analysis. Exp. Hematol. Oncol. 2019;8:26. doi: 10.1186/s40164-019-0150-0.</cite> [<a href="https://doi.org/10.1186/s40164-019-0150-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6815037/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31673481/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp.%20Hematol.%20Oncol.&amp;title=The%20efficacy%20and%20safety%20of%20combination%20of%20PD-1%20and%20CTLA-4%20inhibitors:%20A%20meta-analysis&amp;author=K.%20Wu&amp;author=M.%20Yi&amp;author=S.%20Qin&amp;author=Q.%20Chu&amp;author=X.%20Zheng&amp;volume=8&amp;publication_year=2019&amp;pages=26&amp;pmid=31673481&amp;doi=10.1186/s40164-019-0150-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B12-medsci-13-00143">
<span class="label">12.</span><cite>Tanvetyanon T., Gray J.E., Antonia S.J. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Expert Opin. Biol. Ther. 2017;17:305–312. doi: 10.1080/14712598.2017.1280454.</cite> [<a href="https://doi.org/10.1080/14712598.2017.1280454" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28064556/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opin.%20Biol.%20Ther.&amp;title=PD-1%20checkpoint%20blockade%20alone%20or%20combined%20PD-1%20and%20CTLA-4%20blockade%20as%20immunotherapy%20for%20lung%20cancer?&amp;author=T.%20Tanvetyanon&amp;author=J.E.%20Gray&amp;author=S.J.%20Antonia&amp;volume=17&amp;publication_year=2017&amp;pages=305-312&amp;pmid=28064556&amp;doi=10.1080/14712598.2017.1280454&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B13-medsci-13-00143">
<span class="label">13.</span><cite>Buchbinder E.I., Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am. J. Clin. Oncol. 2016;39:98–106. doi: 10.1097/COC.0000000000000239.</cite> [<a href="https://doi.org/10.1097/COC.0000000000000239" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4892769/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26558876/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20J.%20Clin.%20Oncol.&amp;title=CTLA-4%20and%20PD-1%20Pathways:%20Similarities,%20Differences,%20and%20Implications%20of%20Their%20Inhibition&amp;author=E.I.%20Buchbinder&amp;author=A.%20Desai&amp;volume=39&amp;publication_year=2016&amp;pages=98-106&amp;pmid=26558876&amp;doi=10.1097/COC.0000000000000239&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B14-medsci-13-00143">
<span class="label">14.</span><cite>Cheng W., Kang K., Zhao A., Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. J. Hematol. Oncol. 2024;17:54. doi: 10.1186/s13045-024-01581-2.</cite> [<a href="https://doi.org/10.1186/s13045-024-01581-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11283714/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39068460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Hematol.%20Oncol.&amp;title=Dual%20blockade%20immunotherapy%20targeting%20PD-1/PD-L1%20and%20CTLA-4%20in%20lung%20cancer&amp;author=W.%20Cheng&amp;author=K.%20Kang&amp;author=A.%20Zhao&amp;author=Y.%20Wu&amp;volume=17&amp;publication_year=2024&amp;pages=54&amp;pmid=39068460&amp;doi=10.1186/s13045-024-01581-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B15-medsci-13-00143">
<span class="label">15.</span><cite>Xia L., Liu Y., Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist. 2019;24((Suppl. 1)):S31–S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.</cite> [<a href="https://doi.org/10.1634/theoncologist.2019-IO-S1-s05" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6394772/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30819829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=PD-1/PD-L1%20Blockade%20Therapy%20in%20Advanced%20Non-Small-Cell%20Lung%20Cancer:%20Current%20Status%20and%20Future%20Directions&amp;author=L.%20Xia&amp;author=Y.%20Liu&amp;author=Y.%20Wang&amp;volume=24&amp;issue=(Suppl.%201)&amp;publication_year=2019&amp;pages=S31-S41&amp;pmid=30819829&amp;doi=10.1634/theoncologist.2019-IO-S1-s05&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B16-medsci-13-00143">
<span class="label">16.</span><cite>Wang J., Peng W., Jiang M., Wu L. Research Progress of Anti-angiogenic Agents Combined with Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi. 2021;24:196–203. doi: 10.3779/J.ISSN.1009-3419.2021.101.05.</cite> [<a href="https://doi.org/10.3779/J.ISSN.1009-3419.2021.101.05" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8143969/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33819970/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Zhongguo%20Fei%20Ai%20Za%20Zhi.&amp;title=Research%20Progress%20of%20Anti-angiogenic%20Agents%20Combined%20with%20Immunotherapy%20in%20Patients%20with%20Advanced%20Non-small%20Cell%20Lung%20Cancer&amp;author=J.%20Wang&amp;author=W.%20Peng&amp;author=M.%20Jiang&amp;author=L.%20Wu&amp;volume=24&amp;publication_year=2021&amp;pages=196-203&amp;pmid=33819970&amp;doi=10.3779/J.ISSN.1009-3419.2021.101.05&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B17-medsci-13-00143">
<span class="label">17.</span><cite>Xu Z., Li J. Review on the combination strategy of anti-angiogenic agents and other anti-tumor agents in advanced non-small cell lung cancer. Chin. J. Lung Cancer. 2021;24:357–364. doi: 10.3779/j.issn.1009-3419.2021.101.16.</cite> [<a href="https://doi.org/10.3779/j.issn.1009-3419.2021.101.16" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8174111/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34034460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chin.%20J.%20Lung%20Cancer&amp;title=Review%20on%20the%20combination%20strategy%20of%20anti-angiogenic%20agents%20and%20other%20anti-tumor%20agents%20in%20advanced%20non-small%20cell%20lung%20cancer&amp;author=Z.%20Xu&amp;author=J.%20Li&amp;volume=24&amp;publication_year=2021&amp;pages=357-364&amp;pmid=34034460&amp;doi=10.3779/j.issn.1009-3419.2021.101.16&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B18-medsci-13-00143">
<span class="label">18.</span><cite>Ren S., Xiong X., You H., Shen J., Zhou P. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. Front. Immunol. 2021;12:689132.  doi: 10.3389/fimmu.2021.689132.</cite> [<a href="https://doi.org/10.3389/fimmu.2021.689132" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8206805/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34149730/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Immunol.&amp;title=The%20Combination%20of%20Immune%20Checkpoint%20Blockade%20and%20Angiogenesis%20Inhibitors%20in%20the%20Treatment%20of%20Advanced%20Non-Small%20Cell%20Lung%20Cancer&amp;author=S.%20Ren&amp;author=X.%20Xiong&amp;author=H.%20You&amp;author=J.%20Shen&amp;author=P.%20Zhou&amp;volume=12&amp;publication_year=2021&amp;pages=689132&amp;pmid=34149730&amp;doi=10.3389/fimmu.2021.689132&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B19-medsci-13-00143">
<span class="label">19.</span><cite>Rendon A., Rayi A. Nivolumab. StatPearls, 28 February 2024.  [(accessed on 2 January 2025)]; Available online:  <a href="https://www.ncbi.nlm.nih.gov/books/NBK567801/" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/books/NBK567801/</a></cite>
</li>
<li id="B20-medsci-13-00143">
<span class="label">20.</span><cite>Guo L., Zhang H., Chen B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J. Cancer. 2017;8:410–416. doi: 10.7150/jca.17144.</cite> [<a href="https://doi.org/10.7150/jca.17144" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5332892/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28261342/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Cancer&amp;title=Nivolumab%20as%20Programmed%20Death-1%20(PD-1)%20Inhibitor%20for%20Targeted%20Immunotherapy%20in%20Tumor&amp;author=L.%20Guo&amp;author=H.%20Zhang&amp;author=B.%20Chen&amp;volume=8&amp;publication_year=2017&amp;pages=410-416&amp;pmid=28261342&amp;doi=10.7150/jca.17144&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B21-medsci-13-00143">
<span class="label">21.</span><cite>Garcia J., Hurwitz H.I., Sandler A.B., Miles D., Coleman R.L., Deurloo R., Chinot O.L. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 2020;86:102017. doi: 10.1016/j.ctrv.2020.102017.</cite> [<a href="https://doi.org/10.1016/j.ctrv.2020.102017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32335505/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Treat.%20Rev.&amp;title=Bevacizumab%20(Avastin%C2%AE)%20in%20cancer%20treatment:%20A%20review%20of%2015%20years%20of%20clinical%20experience%20and%20future%20outlook&amp;author=J.%20Garcia&amp;author=H.I.%20Hurwitz&amp;author=A.B.%20Sandler&amp;author=D.%20Miles&amp;author=R.L.%20Coleman&amp;volume=86&amp;publication_year=2020&amp;pages=102017&amp;pmid=32335505&amp;doi=10.1016/j.ctrv.2020.102017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B22-medsci-13-00143">
<span class="label">22.</span><cite>Assoun S., Brosseau S., Steinmetz C., Gounant V., Zalcman G. Bevacizumab in advanced lung cancer: State of the art. Future Oncol. 2017;13:2515–2535. doi: 10.2217/fon-2017-0302.</cite> [<a href="https://doi.org/10.2217/fon-2017-0302" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28812378/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Future%20Oncol.&amp;title=Bevacizumab%20in%20advanced%20lung%20cancer:%20State%20of%20the%20art&amp;author=S.%20Assoun&amp;author=S.%20Brosseau&amp;author=C.%20Steinmetz&amp;author=V.%20Gounant&amp;author=G.%20Zalcman&amp;volume=13&amp;publication_year=2017&amp;pages=2515-2535&amp;pmid=28812378&amp;doi=10.2217/fon-2017-0302&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B23-medsci-13-00143">
<span class="label">23.</span><cite>de Aguiar R.B., de Moraes J.Z. Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors. Front. Immunol. 2019;10:1023.  doi: 10.3389/fimmu.2019.01023.</cite> [<a href="https://doi.org/10.3389/fimmu.2019.01023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6530399/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31156623/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Immunol.&amp;title=Exploring%20the%20immunological%20mechanisms%20underlying%20the%20anti-vascular%20endothelial%20growth%20factor%20activity%20in%20tumors&amp;author=R.B.%20de%20Aguiar&amp;author=J.Z.%20de%20Moraes&amp;volume=10&amp;publication_year=2019&amp;pages=1023&amp;pmid=31156623&amp;doi=10.3389/fimmu.2019.01023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B24-medsci-13-00143">
<span class="label">24.</span><cite>Kim H.R., Sugawara S., Lee J., Kang J., Inui N., Hida T., Lee K.H., Yoshida T., Tanaka H., Yang C., et al.  First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial. Cancer Med. 2023;12:17061–17067. doi: 10.1002/cam4.6348.</cite> [<a href="https://doi.org/10.1002/cam4.6348" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10501244/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37641544/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Med.&amp;title=First-line%20nivolumab,%20paclitaxel,%20carboplatin,%20and%20bevacizumab%20for%20advanced%20non-squamous%20non-small%20cell%20lung%20cancer:%20Updated%20survival%20analysis%20of%20the%20ONO-4538-52/TASUKI-52%20randomized%20controlled%20trial&amp;author=H.R.%20Kim&amp;author=S.%20Sugawara&amp;author=J.%20Lee&amp;author=J.%20Kang&amp;author=N.%20Inui&amp;volume=12&amp;publication_year=2023&amp;pages=17061-17067&amp;pmid=37641544&amp;doi=10.1002/cam4.6348&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B25-medsci-13-00143">
<span class="label">25.</span><cite>Sugawara S., Lee J.-S., Kang J.-H., Kim H., Inui N., Hida T., Lee K., Yoshida T., Tanaka H., Yang C.-T., et al.  Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann. Oncol. 2021;32:1137–1147. doi: 10.1016/j.annonc.2021.06.004.</cite> [<a href="https://doi.org/10.1016/j.annonc.2021.06.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34139272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=Nivolumab%20with%20carboplatin,%20paclitaxel,%20and%20bevacizumab%20for%20first-line%20treatment%20of%20advanced%20nonsquamous%20non-small-cell%20lung%20cancer&amp;author=S.%20Sugawara&amp;author=J.-S.%20Lee&amp;author=J.-H.%20Kang&amp;author=H.%20Kim&amp;author=N.%20Inui&amp;volume=32&amp;publication_year=2021&amp;pages=1137-1147&amp;pmid=34139272&amp;doi=10.1016/j.annonc.2021.06.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B26-medsci-13-00143">
<span class="label">26.</span><cite>Kanda S., Ohe Y., Goto Y., Horinouchi H., Fujiwara Y., Nokihara H., Yamamoto N., Yamamoto T., Tamura T. Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. Cancer Sci. 2020;111:1933–1942. doi: 10.1111/cas.14410.</cite> [<a href="https://doi.org/10.1111/cas.14410" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7293099/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32277531/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Sci.&amp;title=Five-year%20safety%20and%20efficacy%20data%20from%20a%20phase%20Ib%20study%20of%20nivolumab%20and%20chemotherapy%20in%20advanced%20non-small-cell%20lung%20cancer&amp;author=S.%20Kanda&amp;author=Y.%20Ohe&amp;author=Y.%20Goto&amp;author=H.%20Horinouchi&amp;author=Y.%20Fujiwara&amp;volume=111&amp;publication_year=2020&amp;pages=1933-1942&amp;pmid=32277531&amp;doi=10.1111/cas.14410&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B27-medsci-13-00143">
<span class="label">27.</span><cite>Wu L., Yu Y., Zhou J., Wang X., Li J., Wang Y. Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: Case report and review of the literature. Immunotherapy. 2020;12:957–964. doi: 10.2217/imt-2020-0038.</cite> [<a href="https://doi.org/10.2217/imt-2020-0038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32686549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunotherapy&amp;title=Mechanism%20of%20acquired%20resistance%20to%20nivolumab%20in%20lung%20squamous%20cell%20carcinoma:%20Case%20report%20and%20review%20of%20the%20literature&amp;author=L.%20Wu&amp;author=Y.%20Yu&amp;author=J.%20Zhou&amp;author=X.%20Wang&amp;author=J.%20Li&amp;volume=12&amp;publication_year=2020&amp;pages=957-964&amp;pmid=32686549&amp;doi=10.2217/imt-2020-0038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B28-medsci-13-00143">
<span class="label">28.</span><cite>FDA  Opdivo-Highlights of Prescribing Information.  [(accessed on 9 September 2024)];2022  Available online:  <a href="http://www.fda.gov/medwatch" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.fda.gov/medwatch</a>.</cite>
</li>
<li id="B29-medsci-13-00143">
<span class="label">29.</span><cite>Barrios D.M., Do M.H., Phillips G.S., Postow M.A., Akaike T., Nghiem P., Lacouture M.E. CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies. J. Am. Acad. Dermatol. 2020;83:1239. doi: 10.1016/j.jaad.2020.03.131.</cite> [<a href="https://doi.org/10.1016/j.jaad.2020.03.131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7572574/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32461079/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=CME%20Part%20I:%20Immune%20checkpoint%20inhibitors%20to%20treat%20cutaneous%20malignancies&amp;author=D.M.%20Barrios&amp;author=M.H.%20Do&amp;author=G.S.%20Phillips&amp;author=M.A.%20Postow&amp;author=T.%20Akaike&amp;volume=83&amp;publication_year=2020&amp;pages=1239&amp;pmid=32461079&amp;doi=10.1016/j.jaad.2020.03.131&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B30-medsci-13-00143">
<span class="label">30.</span><cite>Lin X., Kang K., Chen P., Zeng Z., Li G., Xiong W., Yi M., Xiang B. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol. Cancer. 2024;23:108. doi: 10.1186/s12943-024-02023-w.</cite> [<a href="https://doi.org/10.1186/s12943-024-02023-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11102195/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38762484/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cancer&amp;title=Regulatory%20mechanisms%20of%20PD-1/PD-L1%20in%20cancers&amp;author=X.%20Lin&amp;author=K.%20Kang&amp;author=P.%20Chen&amp;author=Z.%20Zeng&amp;author=G.%20Li&amp;volume=23&amp;publication_year=2024&amp;pages=108&amp;pmid=38762484&amp;doi=10.1186/s12943-024-02023-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B31-medsci-13-00143">
<span class="label">31.</span><cite>FDA  Avastin-Highlights of Prescribing Information.  [(accessed on 9 September 2024)];2014  Available online:  <a href="http://www.fda.gov/medwatch" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.fda.gov/medwatch</a>.</cite>
</li>
<li id="B32-medsci-13-00143">
<span class="label">32.</span><cite>Haibe Y., Kreidieh M., El Hajj H., Khalifeh I., Mukherji D., Temraz S., Shamseddine A. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front. Oncol. 2020;10:221.  doi: 10.3389/fonc.2020.00221.</cite> [<a href="https://doi.org/10.3389/fonc.2020.00221" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7056882/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32175278/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=Resistance%20Mechanisms%20to%20Anti-angiogenic%20Therapies%20in%20Cancer&amp;author=Y.%20Haibe&amp;author=M.%20Kreidieh&amp;author=H.%20El%20Hajj&amp;author=I.%20Khalifeh&amp;author=D.%20Mukherji&amp;volume=10&amp;publication_year=2020&amp;pages=221&amp;pmid=32175278&amp;doi=10.3389/fonc.2020.00221&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B33-medsci-13-00143">
<span class="label">33.</span><cite>Itatani Y., Kawada K., Yamamoto T., Sakai Y. Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway. Int. J. Mol. Sci. 2018;19:1232.  doi: 10.3390/ijms19041232.</cite> [<a href="https://doi.org/10.3390/ijms19041232" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5979390/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29670046/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=Resistance%20to%20Anti-Angiogenic%20Therapy%20in%20Cancer%E2%80%94Alterations%20to%20Anti-VEGF%20Pathway&amp;author=Y.%20Itatani&amp;author=K.%20Kawada&amp;author=T.%20Yamamoto&amp;author=Y.%20Sakai&amp;volume=19&amp;publication_year=2018&amp;pages=1232&amp;pmid=29670046&amp;doi=10.3390/ijms19041232&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B34-medsci-13-00143">
<span class="label">34.</span><cite>Hellmann M.D., Nathanson T., Rizvi H., Creelan B.C., Sanchez-Vega F., Ahuja A., Ni A., Novik J.B., Mangarin L.M., Abu-Akeel M., et al.  Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018;33:843. doi: 10.1016/j.ccell.2018.03.018.</cite> [<a href="https://doi.org/10.1016/j.ccell.2018.03.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5953836/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29657128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Genomic%20Features%20of%20Response%20to%20Combination%20Immunotherapy%20in%20Patients%20with%20Advanced%20Non-Small-Cell%20Lung%20Cancer&amp;author=M.D.%20Hellmann&amp;author=T.%20Nathanson&amp;author=H.%20Rizvi&amp;author=B.C.%20Creelan&amp;author=F.%20Sanchez-Vega&amp;volume=33&amp;publication_year=2018&amp;pages=843&amp;pmid=29657128&amp;doi=10.1016/j.ccell.2018.03.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B35-medsci-13-00143">
<span class="label">35.</span><cite>Nagasaki J., Ishino T., Togashi Y. Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci. 2022;113:3303. doi: 10.1111/cas.15497.</cite> [<a href="https://doi.org/10.1111/cas.15497" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9530865/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35848888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Sci.&amp;title=Mechanisms%20of%20resistance%20to%20immune%20checkpoint%20inhibitors&amp;author=J.%20Nagasaki&amp;author=T.%20Ishino&amp;author=Y.%20Togashi&amp;volume=113&amp;publication_year=2022&amp;pages=3303&amp;pmid=35848888&amp;doi=10.1111/cas.15497&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B36-medsci-13-00143">
<span class="label">36.</span><cite>Vokes N.I., Pan K., Le X. Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. Ther. Adv. Med. Oncol. 2023;15:17588359231161408. doi: 10.1177/17588359231161409.</cite> [<a href="https://doi.org/10.1177/17588359231161409" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10026098/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36950275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ther.%20Adv.%20Med.%20Oncol.&amp;title=Efficacy%20of%20immunotherapy%20in%20oncogene-driven%20non-small-cell%20lung%20cancer&amp;author=N.I.%20Vokes&amp;author=K.%20Pan&amp;author=X.%20Le&amp;volume=15&amp;publication_year=2023&amp;pages=17588359231161408&amp;pmid=36950275&amp;doi=10.1177/17588359231161409&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B37-medsci-13-00143">
<span class="label">37.</span><cite>Zhao Y., Guo S., Deng J., Shen J., Du F., Wu X., Chen Y., Li M., Chen M., Li X., et al.  VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. Int. J. Biol. Sci. 2022;18:3845–3858. doi: 10.7150/IJBS.70958.</cite> [<a href="https://doi.org/10.7150/IJBS.70958" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9254480/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35813484/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Biol.%20Sci.&amp;title=VEGF/VEGFR-Targeted%20Therapy%20and%20Immunotherapy%20in%20Non-small%20Cell%20Lung%20Cancer:%20Targeting%20the%20Tumor%20Microenvironment&amp;author=Y.%20Zhao&amp;author=S.%20Guo&amp;author=J.%20Deng&amp;author=J.%20Shen&amp;author=F.%20Du&amp;volume=18&amp;publication_year=2022&amp;pages=3845-3858&amp;pmid=35813484&amp;doi=10.7150/IJBS.70958&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B38-medsci-13-00143">
<span class="label">38.</span><cite>Melosky B., Juergens R., Hirsh V., McLeod D., Leighl N., Tsao M.-S., Card P.B., Chu Q. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. Oncologist. 2020;25:64–77. doi: 10.1634/theoncologist.2019-0027.</cite> [<a href="https://doi.org/10.1634/theoncologist.2019-0027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6964132/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31138727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=Amplifying%20Outcomes:%20Checkpoint%20Inhibitor%20Combinations%20in%20First-Line%20Non-Small%20Cell%20Lung%20Cancer&amp;author=B.%20Melosky&amp;author=R.%20Juergens&amp;author=V.%20Hirsh&amp;author=D.%20McLeod&amp;author=N.%20Leighl&amp;volume=25&amp;publication_year=2020&amp;pages=64-77&amp;pmid=31138727&amp;doi=10.1634/theoncologist.2019-0027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B39-medsci-13-00143">
<span class="label">39.</span><cite>Kato Y., Tabata K., Kimura T., Yachie-Kinoshita A., Ozawa Y., Yamada K., Ito J., Tachino S., Hori Y., Matsuki M., et al.  Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE. 2019;14:e0212513.  doi: 10.1371/JOURNAL.PONE.0212513.</cite> [<a href="https://doi.org/10.1371/JOURNAL.PONE.0212513" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6392299/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30811474/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Lenvatinib%20plus%20anti-PD-1%20antibody%20combination%20treatment%20activates%20CD8+%20T%20cells%20through%20reduction%20of%20tumor-associated%20macrophage%20and%20activation%20of%20the%20interferon%20pathway&amp;author=Y.%20Kato&amp;author=K.%20Tabata&amp;author=T.%20Kimura&amp;author=A.%20Yachie-Kinoshita&amp;author=Y.%20Ozawa&amp;volume=14&amp;publication_year=2019&amp;pages=e0212513&amp;pmid=30811474&amp;doi=10.1371/JOURNAL.PONE.0212513&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B40-medsci-13-00143">
<span class="label">40.</span><cite>Herbst R.S., Arkenau H.T., Bendell J., Arrowsmith E., Wermke M., Soriano A., Penel N., Santana-Davila R., Bischoff H., Chau I., et al.  Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. J. Thorac. Oncol. 2021;16:289–298. doi: 10.1016/j.jtho.2020.10.004.</cite> [<a href="https://doi.org/10.1016/j.jtho.2020.10.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33068794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=Phase%201%20Expansion%20Cohort%20of%20Ramucirumab%20Plus%20Pembrolizumab%20in%20Advanced%20Treatment-Naive%20NSCLC&amp;author=R.S.%20Herbst&amp;author=H.T.%20Arkenau&amp;author=J.%20Bendell&amp;author=E.%20Arrowsmith&amp;author=M.%20Wermke&amp;volume=16&amp;publication_year=2021&amp;pages=289-298&amp;pmid=33068794&amp;doi=10.1016/j.jtho.2020.10.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No new data were created or analyzed in this study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Medical Sciences are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.3390/medsci13030143"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/medsci-13-00143.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (979.2 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12371936/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12371936/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12371936%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371936/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12371936/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12371936/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40843765/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12371936/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40843765/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12371936/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12371936/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="u2ZQk0XwViLv9w3OBYwDyWQO8iIPfsdjqVCRCKzfwT206oTtGcUz45zJSdv2QTNF">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
